DEA observed large quantities of fentanyl entering streets without taking action, according to newly released records.
DEA Under Scrutiny for Handling Fentanyl Crisis in New Mexico
The U.S. Drug Enforcement Administration (DEA) is facing significant criticism for its handling of a fentanyl crisis in New Mexico, identified as one of the deadliest drug epidemics in American history. Between 2023 and 2025, the agency reportedly allowed the distribution of hundreds of thousands of fentanyl pills on the streets of New Mexico, raising concerns about public safety and compliance with federal drug policies.
Investigations conducted by Media News Source indicate that DEA agents consistently monitored fentanyl shipments yet refrained from seizing them. This strategy was justified by a desire to build larger criminal cases against traffickers of the synthetic opioid, which the White House designated as a weapon of mass destruction in 2025. However, critics argue that this approach has endangered communities in Albuquerque and surrounding areas, potentially in violation of U.S. Justice Department regulations designed to protect the public from drug harm.
Former DEA Special Agent David Howell has emerged as a prominent whistleblower, voicing concerns that DEA practices have effectively poisoned communities in pursuit of larger drug trafficking operations. Howell’s complaints assert that, through deliberate negligence, agents have risked lives while failing to account for the consequences of allowing substantial quantities of fentanyl to remain on the streets.
The inherent dangers of fentanyl, which can be lethal in minuscule amounts, have compelled the DEA to reassess conventional drug enforcement tactics. Guidelines from the Justice Department encourage the seizure of fentanyl whenever practicable, particularly given its escalating death toll. In 2021, while overdose fatalities nationwide saw a 14% decline, New Mexico reported a staggering 21% increase in overdose deaths, underscoring the urgent need for effective intervention.
Alex Uballez, a former U.S. attorney for New Mexico, defended the DEA’s controversial strategy as a necessary measure to gather crucial intelligence on major drug trafficking networks. He argued that dismantling larger organizations would ultimately save more lives than seizing every small shipment of drugs. Yet, this line of reasoning has not alleviated fears regarding the potential impact on public welfare.
This situation culminated in a historic bust announced in May 2025, wherein federal authorities confiscated over three million fentanyl pills—a reflective outcome of the very investigations that allowed earlier shipments to circulate. However, the decisions to permit these drugs to flow into local markets have been met with skepticism, particularly from public health advocates and law enforcement critics.
The DEA maintains that its actions adhered to legal standards and were strategic responses to rising drug threats, asserting that suggestions of willful negligence mischaracterize the facts. Nonetheless, the agency’s reliance on surveillance over immediate action raises pressing ethical dilemmas amid an ongoing opioid crisis that continues to plague numerous communities across New Mexico.
The complex dynamics between law enforcement objectives and public safety remain an area of contention, prompting calls for greater transparency and accountability within the DEA as it navigates a rapidly changing landscape of drug trafficking and addiction.
